These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32556142)

  • 1. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
    Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S
    Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
    Schmidt PJ; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2021 Feb; 96(2):251-257. PubMed ID: 33180328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.
    Guo S; Casu C; Gardenghi S; Booten S; Aghajan M; Peralta R; Watt A; Freier S; Monia BP; Rivella S
    J Clin Invest; 2013 Apr; 123(4):1531-41. PubMed ID: 23524968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
    Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD
    Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
    Artuso I; Lidonnici MR; Altamura S; Mandelli G; Pettinato M; Muckenthaler MU; Silvestri L; Ferrari G; Camaschella C; Nai A
    Blood; 2018 Nov; 132(21):2286-2297. PubMed ID: 30209118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
    Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C
    Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
    Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
    Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6.
    Lee P; Hsu MH; Welser-Alves J; Peng H
    Blood Cells Mol Dis; 2012 Mar; 48(3):173-8. PubMed ID: 22244935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
    Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
    Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice.
    Nai A; Pellegrino RM; Rausa M; Pagani A; Boero M; Silvestri L; Saglio G; Roetto A; Camaschella C
    Haematologica; 2014 Jun; 99(6):1016-21. PubMed ID: 24658816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
    Casu C; Aghajan M; Oikonomidou PR; Guo S; Monia BP; Rivella S
    Haematologica; 2016 Jan; 101(1):e8-e11. PubMed ID: 26405152
    [No Abstract]   [Full Text] [Related]  

  • 12. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
    Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
    Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
    Tanzi E; Di Modica SM; Bordini J; Olivari V; Pagani A; Furiosi V; Silvestri L; Campanella A; Nai A
    Am J Hematol; 2024 Jul; 99(7):1313-1325. PubMed ID: 38629683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice.
    Wake M; Palin A; Belot A; Berger M; Lorgouilloux M; Bichon M; Papworth J; Bayliss L; Grimshaw B; Rynkiewicz N; Paterson J; Poindron A; Spearing E; Carter E; Hudson R; Campbell M; Petzer V; Besson-Fournier C; Latour C; Largounez A; Gourbeyre O; Fay A; Coppin H; Roth MP; Theurl I; Germaschewski V; Meynard D
    Blood Adv; 2024 Apr; 8(8):1898-1907. PubMed ID: 38241484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
    Di Modica SM; Tanzi E; Olivari V; Lidonnici MR; Pettinato M; Pagani A; Tiboni F; Furiosi V; Silvestri L; Ferrari G; Rivella S; Nai A
    Am J Hematol; 2022 Oct; 97(10):1324-1336. PubMed ID: 36071579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical role for murine transferrin receptor 2 in erythropoiesis during iron restriction.
    Wallace DF; Secondes ES; Rishi G; Ostini L; McDonald CJ; Lane SW; Vu T; Hooper JD; Velasco G; Ramsay AJ; Lopez-Otin C; Subramaniam VN
    Br J Haematol; 2015 Mar; 168(6):891-901. PubMed ID: 25403101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
    Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease.
    Olivari V; Di Modica SM; Lidonnici MR; Aghajan M; Cordero-Sanchez C; Tanzi E; Pettinato M; Pagani A; Tiboni F; Silvestri L; Guo S; Ferrari G; Nai A
    Kidney Int; 2023 Jul; 104(1):61-73. PubMed ID: 36990212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erythropoietin administration on proteins participating in iron homeostasis in Tmprss6-mutated mask mice.
    Frýdlová J; Rychtarčíková Z; Gurieva I; Vokurka M; Truksa J; Krijt J
    PLoS One; 2017; 12(10):e0186844. PubMed ID: 29073189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron and hepcidin: a story of recycling and balance.
    Camaschella C
    Hematology Am Soc Hematol Educ Program; 2013; 2013():1-8. PubMed ID: 24319154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.